Probucol-associated tachyarrhythmic events and QT prolongation: Importance of gender

American Heart Journal

Volumn 131, Issue 6, 1996, Pages 1184-1191

  Reinoehl, Joel ^a   Frankovich, Debra ^a   Machado, Christian ^a   Kawasaki, Raymond ^a   Baga, John J ^a   Pires, Luis A ^a   Steinman, Russell T ^a   Fromm, Barbara S ^a   Lehmann, Michael H ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SINAI GRACE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRETYLIUM; DISOPYRAMIDE; LIDOCAINE; PROBUCOL; TRIAMTERENE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOCHOLESTEROLEMIA; LONG QT SYNDROME; MALE; PRIORITY JOURNAL; QT INTERVAL; SEX DIFFERENCE; TACHYCARDIA;

EID: 0029884597     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90095-2     Document Type: Article

References (36)

1. Buckley M, Goa K, Price A, Brogden R. Probucol: a reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 1989;37:761-800.
2. Schwartz C. The probucol experience: a review of the past and a look at the future. Am J Cardiol 1988;62:1B-5B.
3. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidation modification of low density lipoprotein. J Clin Invest 1986;77:641-4.
4. Anderson TJ, Meredith IT, Yeung AL, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
5. Klein L. QT interval prolongation produced by probucol. Arch Intern Med 1981;141:1102-3.
6. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-72.
7. Miettinen TA, Huttunen JK, Kuusi T, et al. Clinical experience with probucol with special emphasis on mode of action and long-term treatment. Artery 1982;10(1):35-43.
8. Naukkarinen V, Strandberg T, VanHanen H, et al. Probucol-induced electrocardiographic changes in a five year primary prevention of vascular diseases. Curr Ther Res 1989;45:232-7.
9. Makkar R, Fromm B, Steinman R, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
10. Archibald D, Quart B, Hardy S, et al. Torsades de pointes with sotalol: relationship of gender to risk [Abstract]. J Am Coll Cardiol 1994:279A.
11. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-70.
12. Kajinami K, Takekoshi N, Mabuchi H. Propranolol for probucolinduced QT prolongation with polymorphic ventricular tachycardia. Lancet 1993;341:124-5.
13. Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (torsades de pointes) associated with the use of probucol. N Engl J Med 1992;326:1435-6.
14. Cavallini B, Spinolo L, Guadagni C, et al. Probucol ed aritmie ventricolari maligne. Minerva Cardioangiol 1987;35:99-100.
15. Matsuhashi H, Onodera S, Kawamura Y, et al. Probucol-induced QT prolongation and torsades de pointes. Jpn J Med 1989;28:612-15.
16. Quek DK, H'ng DK. Torsades de pointes and sudden death associated with diabetic autonomic diarrhoea - a case report. Singapore Med J 1993;34:266-70.
17. Romics L, Littmann L, Laszlo Z, et al. Effect of QT/QS2 relation and systolic time intervals. Int J Cardiol 1988;19:303-8.
18. Sasaki N, Saku K, Morde K, et al. Long term administration of probucol and QTc interval prolongation. Artery 1993;20:115-21.
19. Ohya Y, Kumamota K, Abe I, et al. Factors related to QT interval prolongation during probucol treatment. Eur J Clin Pharmacol 1993;45:47-52.
20. Kosasayama A, Yoshida M, Okada S, et al. Post-marking surveillance of probucol (siniestal) in Japan. Artery 1992;19:147-61.
21. Browne K, Prystowsky E, Heger J, et al. Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced for a drug. Am Heart J 1984;107:680-4.
22. Graham I, Ronan G, Comerford D, et al. Probucol, blood lipids and the ECG QTc interval. Irish Med J 1986;79:45-7.
23. DuJovne CA, Atkins F, Wong B, et al. Electrocardiographic effects of probucol: a controlled prospective clinical trial. Eur J Clin Pharmacol 1984;26:735-9.
24. McCaughan D. Probucol and the QT interval [Letter]. Lancet 1982; 2:161.
25. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83.
26. Abinader EG, Shahar J. Possible female preponderance in prenylamine-induced torsade de pointes tachycardia. Cardiology 1983;70:37-40.
27. Kasanuki H, Ohnishi S, Tamura K, et al. Acquired long QT syndrome due to antiarrhythmia drugs and bradyarrhythmias: QT prolongation and ventricular arrhythmias. Ann NY Acad Sci 1992;644:57-73.
28. Fontaine G. A new look at torsades de pointes, QT prolongation and ventricular arrhythmias. Ann NY Acad Sci 1992;644:157-76.
29. Coumel P. Safety of bepridil: from review of the European data. Am J Cardiol 1992;69(suppl):75D-8D.
30. Zipes DP. Proarrhythmic effects of antiarrhythmic drugs. Am J Cardiol 1987;59(suppl):26E-31E.
31. Roden DM. The long QT syndrome and torsade de pointes: basic and clinical aspects. In: El-Sherif N, ed. Cardiac pacing and electrophysiology. 3rd ed. Philadelphia: WB Saunders, 1991:265-84.
32. Benditt DG, Bailin S, Remole S, et al. Proarrhythmia: recognition of patients at risk. J Cardiovasc Electrophysiol 1991;2(suppl):S221-32.
33. Leenhardt A, Coumel P, Slama R. Torsades de pointes. J Cardiovasc Electrophysiol 1992;3:281-92.
34. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
35. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-4.
36. Janssen Pharmaceutica, Inc. Physician advisory letter regarding reports of torsade de pointes with cisapride. Piscataway, N.J.: Janssen Pharmaceutica, Inc., 1995.